Company: TELO
Filing Date: 2025-08-14
Form Type: 10-Q
Source: 0001641172-25-023970
Chunk: 2

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-08-14
Form: 10-Q
Item: Item 1
Chunk 2
---
 (2,179,828) 
     (2,179,828)

    Balances, March 31, 2025 
     29,762,671  
     -  
     32,615,580  
     
     (32,776,686) 
     (161,106)

    Issuance of common stock for cash, net 
     351,633  
     -  
     1,047,769  
     
     -  
     1,047,769 
  
    Issuance of common stock for services 
     400,000  
     -  
     840,000  
     
     -  
     840,000 
  
    Stock based compensation 
     -  
     -  
     3,824,450  
     
     -  
     3,824,450 
  
    Net loss 
     -  
     -  
     -  
     
     (5,069,890) 
     (5,069,890)
  
    Balances, June 30, 2025 
     30,514,304  
     -  
     38,327,799  
     
     (37,846,576) 
     481,223 
  
    Balance 
     30,514,304  
     -  
     38,327,799  
     
     (37,846,576) 
     481,223 

See
notes to condensed unaudited financial statements

5

TELOMIR
PHARMACEUTICALS, INC.

CONDENSED
STATEMENTS OF CASH FLOWS

(Unaudited)

    2025  
    2024 

    Six Months Ended June 30, 

    2025  
    2024 
  
    Cash flows from Operating activities 

    Net loss 
    $(7,249,718) 
    $(7,703,610)
  
    Adjustments to reconcile net loss to net cash used in operations 

    Stock-based compensation expense 
     6,040,136  
     - 
  
    Amortization of debt issuance costs 
     -  
     4,338,543 
  
    Change